clinical trial · NCT05774184
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
Eosinophilic EsophagitisbarzolvolimabMatching Placebo
brief summary
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.
started
Jun 1, 2023
primary completion
Jun 4, 2025
completion
Jan 23, 2026
last updated
Jan 30, 2026
detailed description
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.
official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults With Active Eosinophilic Esophagitis (The "EvolvE" Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol